Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)

• Status: Completed
• Trial end date: 1969-12-31

Summary

The objective of ASSENT 3 was to evaluate the safety and efficacy of full dose tenecteplase with heparin sodium (group A), full dose tenecteplase combined with enoxaparin (group B) and half dose tenecteplase combined with abciximab and heparin sodium (group C).

• Phase: Phase 3

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Abciximab; Antibodies, Monoclonal; Calcium heparin; Enoxaparin; Heparin; Immunoglobulin Fab Fragments; Tenecteplase; Tissue Plasminogen Activator